MeritValue

Inhibitor Therapeutics, Inc.

INTIdata completeness 63%14 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'

The thesis, from the filings

Inhibitor Therapeutics, Inc. earns about -27% on equity, and has bought back 54% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$01————
Net income−$298,6322$12.1M3−$3.03M4−$3.34M5−$3.3M5
Operating cash flow−$220,4336$11.7M7−$2.7M8−$3.23M9−$3.23M9
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$30,62610$12M11$8.84M12$5.61M13$2.38M13
Diluted shares376.2M366.2M172.0M172.3M172.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.07
your share of equity
Profit it earned you last year
−$0.19
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.07 of net worth that earned you −$0.19 last year.

iii. Is this a good business?
Moat signal · return on equity
-27% avg · 5y
FY21 —FY22 146%FY23 -57%FY24 -168%FY25 —

It earned an average -27% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−54% shares · 5y

Share count is down 54% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001193125-22-088832 (Revenues)
  2. 10-K · period ending 2021-12-31 · accession 0001493152-23-010383 (NetIncomeLoss)
  3. 10-K · period ending 2022-12-31 · accession 0001493152-24-011973 (NetIncomeLoss)
  4. 10-K · period ending 2023-12-31 · accession 0001641172-25-001190 (NetIncomeLoss)
  5. 10-K · period ending 2024-12-31 · accession 0001493152-26-012751 (NetIncomeLoss)
  6. 10-K · period ending 2021-12-31 · accession 0001493152-23-010383 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2022-12-31 · accession 0001493152-24-011973 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2023-12-31 · accession 0001641172-25-001190 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2024-12-31 · accession 0001493152-26-012751 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2021-12-31 · accession 0001493152-23-010383 (CashAndCashEquivalentsAtCarryingValue)
  11. 10-K · period ending 2022-12-31 · accession 0001493152-24-011973 (CashAndCashEquivalentsAtCarryingValue)
  12. 10-K · period ending 2023-12-31 · accession 0001641172-25-001190 (CashAndCashEquivalentsAtCarryingValue)
  13. 10-K · period ending 2024-12-31 · accession 0001493152-26-012751 (CashAndCashEquivalentsAtCarryingValue)